← Back to Resources
Insurance

Medicare Advantage lead gen: what changed this AEP

New CMS marketing rules, real carrier exits, and a well-funded new entrant are all landing in the same enrollment window. Here's what actually shifted.

AEP 2026 runs October 15 through December 7, enrolling beneficiaries into 2027 Medicare Advantage and Part D plans. Every year brings some regulatory noise into this window — 2026 brought three changes worth actually tracking, because each one touches lead economics directly.

The CMS marketing rules got friendlier, not stricter

CMS published the Contract Year 2027 Medicare Advantage and Part D Final Rule on April 6, 2026, with marketing and communications provisions taking effect October 1 — right as AEP opens. The headline change: the 48-hour Scope of Appointment waiting period is gone, along with the 12-hour buffer that used to separate educational events from marketing events. TPMO disclaimer requirements are also changing. Net effect for advertisers and the agents they route to: less administrative friction between a qualified lead and an actual enrollment conversation.

Carrier footprints actually shrank

2026 brought a meaningfully larger round of county-level exits from UnitedHealthcare, Humana, and Aetna than the market has seen in recent years — reported figures put it at 500+ net county exits and roughly 2.6 million displaced MA-PD enrollees, concentrated in rural counties, New England, and the Midwest. That's not just a headline; it changes which counties a given lead can actually convert in. Buy-box and panel-mapping assumptions that held for years need a genuine re-check rather than a rollover from last AEP.

AEP still drives roughly 60–70% of annual Medicare lead value. Every carrier, FMO, and agent concentrates acquisition in the same eight-week window — which is exactly why small shifts in carrier footprint and consent rules move pricing so fast.

SNP is the quiet growth line

Special Needs Plan enrollment runs year-round under SEP rather than being confined to AEP, and carriers are leaning into it — Humana's D-SNP expansion into Illinois and C-SNP expansion into Idaho, Maine, and New Jersey are recent examples of the broader shift toward SNP capitation. For lead generation specifically, that means SNP-qualified intake — dual-eligibility verification, chronic-condition pre-qualification, low-income subsidy screening — is becoming a distinct, higher-margin lane rather than a subset of general MA volume.

New capital is entering the funnel

Chapter, a Medicare shopping platform, closed a $100M Series E in April 2026 led by Generation Investment Management. The immediate effect on lead economics is modest — expected to show up as incremental paid-media bid pressure on the highest-intent surfaces rather than a wholesale repricing — but it's a signal that top-of-funnel competition for Medicare intent keeps intensifying, not easing.

What this means for lead pricing

Qualified MA lead pricing during AEP has historically run well above off-season rates — often $70–100+ during the October 15–November 15 peak versus $40–55 in the off-season — and nothing about 2026's changes points toward that compressing. If anything, tighter carrier availability in specific counties plus new funded entrants pushing bid pressure argues for planning around AEP premiums rather than against them.

What to actually do with this

  • Re-verify county-level buyer availability before committing AEP budget to a geography that assumed last year's carrier map.
  • Build or route SNP-specific intake separately from general MA volume — the qualification criteria and margin profile are different.
  • Keep speed-to-lead tight. A beneficiary contacted within minutes of a request still converts at a far higher rate than one reached the next day.
  • Document consent on every lead — TCPA exposure didn't go away just because the one-to-one rule did.

Want to talk specifics?

Our team can walk through how this applies to your vertical and volume.